Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ: CERT )

10.71 +0.16 (+1.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies
New IRS program launching for free tax filing could affect tax prep companies like H&R Block and Intuit. Market share drop could impact ETFs. 
Via Benzinga
Recap: Certara Q3 Earnings
Via Benzinga
The Latest Analyst Ratings for Certara
Via Benzinga
The Latest Analyst Ratings for Certara
Via Benzinga
Looking Into Certara's Return On Capital Employed
Via Benzinga
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
Analyst Expectations for Certara's Future
Via Benzinga
Expert Ratings for Certara
Via Benzinga
Certara Reports Third Quarter 2023 Financial Results
Reiterates Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations 
From Certara
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Certara Reports Second Quarter 2023 Financial Results
Provides Update to Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
From Certara
Via GlobeNewswire
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Reports First Quarter 2023 Financial Results
Reiterates 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
Asserts Certara’s leadership in advancing the development and approval of new drugs for patients 
From Certara
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
Via Benzinga
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
From Certara
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
Are These 3 Small Momentum Stocks Setting Up Big Gains?
MINISO, PDF Solutions, and Certara are small stocks with strong price momentum. It’s not unusual for small stocks to show more price momentum than larger peers. 
Via MarketBeat
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.